Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Feb 01

filter terms:

New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Citation

Randy M Stalter, Jared M Baeten, Deborah Donnell, Matthew A Spinelli, David V Glidden, Warren C Rodrigues, Guohong Wang, Michael Vincent, Nelly Mugo, Andrew Mujugira, Mark Marzinke, Craig Hendrix, Monica Gandhi, Partners PrEP Study Team. Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Feb 01;72(3):486-489